Tuesday , September 27 2022

▷ California research team announces promising results for …


Santa Clara, CA (PRNewsvire / -) – Research team Dr. Ing. The Rath Research Institute in California has developed a cancer vaccine that reduces tumor growth. This peptide-based vaccine targets specific enzymes called metalloproteinases (MMPs), which are responsible for tumor growth, the formation of metastases and blood vessels in tumors (angiogenesis). The Dr. The Rath research team showed that the tested mice vaccinated with peptides containing the specific sequences of MMP-2 and MMP-9, and then infected with melanoma cancer cells, had an average tumor reduction of about 76% compared to non-vaccinated animals from the control group. Exceptionally, some vaccinated animals did not develop cancer at all.

The study was published in October 2018 in the online journal Cellular Medicine and Natural Health.

Cancer is still the second largest epidemic in the world. The disease causes more than 7 million deaths each year. This new treatment approach has the potential to drastically change these statistics. Compared with monoclonal antibodies (Mabs) or biosimilar molecules that have recently been developed as anti-cancer agents, the anti-MMP vaccine approach promises to be more effective and more accessible in the global fight against disease. Although Mabs / biosimilars target a specific type of cancer, anti-MMP vaccines can combat all types of cancer. Another advantage is that, unlike Mabs / Biosimilar, where an injection is usually performed once or twice a month, the anti-MMP vaccine should be injected only once and vaccination after several years will be required.

The MMP vaccine, if successfully completed, can be offered to patients from national or international health facilities at a reasonable price.

In order for this valuable technology to be affordable for most patients and nations around the world, the research institute dr. Rath has applied patent protection in many countries. The Institute requires public and government research institutes and other non-profit institutions to develop this promising technology with them, with the goal of successful treatment, prevention and eventual elimination of cancer.

Source: https: //vvv.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-vith-anti-tumor-efficaci-in-vitro-and-in-vivo/

U.S. Pat. 8003110 and 8067009

Photo – https: //mma.prnevsvire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Contact for the media:

Doctor Alekandra Niedzviecki
Managing Director
Doctor Rath Research Institute
E-Mail: [email protected]

Original content: dr. Med. Rath Research Institute, broadcast news aktuell

Source link